- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Can a Negative Biopsy Miss H. pylori?

New study suggests PCR may help when routine biopsy testing is negative.
In 302 gastric biopsy specimens, the microscope and the molecular test told different stories. Routine histology had found no H. pylori, yet PCR detected its DNA. For clinicians accustomed to treating a negative biopsy as the end of the investigation, that discrepancy deserves attention. It also needs careful interpretation.
The finding comes from a retrospective study by Daniel Vizenblit and colleagues at Tzafon Medical Center, Israel. Published online in Diagnostic Microbiology & Infectious Disease on September 18, 2026, the research examined whether molecular testing could recover information from gastric tissue already assessed through routine pathology.
The investigators analysed 830 archived biopsy specimens collected during upper gastrointestinal endoscopy between 2022 and 2024. They extracted DNA from formalin-fixed, paraffin-embedded tissue and used PCR targeting the organism’s glmM/ureC gene. Original histology reports and available rapid urease, culture and immunohistochemistry results provided the comparisons.
Histology had identified H. pylori in 354 specimens, or 42.7%. PCR was positive in 643, or 77.5%, including 341 of the histology-positive samples. Among 476 specimens originally reported negative, 302—63.4%—were PCR-positive.
The tempting conclusion is that microscopy missed all these infections. The evidence does not go that far. PCR identifies bacterial DNA; it cannot, by itself, distinguish living organisms from residual genetic material. The researchers could not definitively establish active infection in every discordant case.
Nevertheless, the additional positive samples had a recognisable pattern. They generally showed fewer inflammatory changes, less endoscopic nodularity and weaker PCR signals than samples positive by both methods. Among cases with available results, rapid urease positivity was 14.7% in the histology-negative/PCR-positive group, compared with 92.5% in those positive by both tests.
These observations are compatible with a lower bacterial burden that is harder to recognise microscopically. They are not proof of it: PCR signal intensity was only a preliminary, semiquantitative measure, rather than a validated bacterial count.
H. pylori can be distributed unevenly across the gastric mucosa, making sampling important. Acid-suppressing medicines may also reduce organism density and alter its distribution. However, proton pump inhibitor use was not systematically recorded in this study, so it cannot explain the discordance with certainty.
Other uncertainties remain. This was a single-centre analysis, and additional tests were available for only selected specimens. All 12 histology-negative/PCR-positive cases with available immunohistochemistry were negative. Culture supported infection in some discordant cases, but the small numbers left many unresolved.
Using histology as the reference, PCR sensitivity was 96.3% and specificity 36.6%. Those figures describe performance against an imperfect comparator. They do not settle which method was correct whenever the results disagreed.
For everyday practice, the study supports reconsidering an unresolved diagnosis rather than replacing histology with PCR. When suspicion remains despite a negative biopsy, review where tissue was sampled, the pathology findings, previous eradication therapy and medicines taken around testing. Further investigation should address the specific uncertainty in that patient.
Archived-tissue PCR may offer additional information without another endoscopy, where a validated service is available. This study, however, did not show that treating the additional PCR-positive patients improved symptoms or prevented later complications.
That distinction matters before prescribing another antibiotic course. A molecular result should be reconciled with the clinical history and other evidence of infection. The useful question is whether further testing will clarify a treatment decision—not simply whether a more sensitive method can produce another positive result.
Dr. Khushboo Nagdev is a Consultant Physician and Diabetologist at Sanjeevan Hospital. She has previously worked as an Attending Consultant in the Department of Internal Medicine and Critical Care. Her areas of expertise include internal medicine, diabetes management, critical care, and the diagnosis and management of various medical conditions.

